Skip to content

Clinical trials

Malaria trials in Zambia

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Malaria Country / region: Zambia Clear all

24 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20061
20072
20092
20102
20141
20151
20163
20191
20201
20212
20231
20246

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed16
Unknown status2
Not yet recruiting1
Recruiting1
Terminated1
Active, not recruiting1
Withdrawn1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
PATH5
Institute of Tropical Medicine, Belgium3
University of Rochester2
Boston University1
Center for International Health and Development1
International Maternal Pediatric Adolescent AIDS Clinical Trials Group1
Johns Hopkins Bloomberg School of Public Health1
London School of Economics and Political Science1
London School of Hygiene and Tropical Medicine1
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Malaria24
Malaria, Falciparum7
Fever3
HIV Infections3
Diarrhea2
Pneumonia2
Anemia1
Asymptomatic Infections1
Brain Injuries1
Coinfection1

Trials

Showing 76 to 24 of 24. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.